Market Place
Market Place
Post Enquiry
FDA approves record eight biosimilars in H1 2024; okays first interchangeable biosimilars for Eylea
Biologics, or complex drugs that are derived from living organisms, have revolutionized treatment of
FDA approvals rise 49% in 2023; CRISPR’s gene editing therapy sees light of day
In 2022, when the
US Food and Drug Administration (FDA) was reeling under the impact of the
pandem
